Infections from respiratory syncytial virus (RSV) in children requiring primary care led to significant societal economic ...

Costs varied across 5 European countries, driven primarily by repeated primary care visits and parental work absences.

Infections from respiratory syncytial virus (RSV) in children requiring primary care led to significant societal economic costs from outpatient treatment and parental work absences in Europe, ...

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.

As winter nears and the cold and flu season sets in, the highly infectious respiratory virus RSV has again begun its spread. So far this year, the National Disease Surveillance System (NDSS ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

The infant mortality national rate dropped to about 5.5 infant deaths per 1,000 live births in 2024, according to provisional data from the Centers for Disease Control and Prevention posted Thursday.